New Zealand markets closed

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5800+0.0236 (+4.24%)
At close: 04:00PM EDT
0.5607 -0.02 (-3.33%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5564
Open0.5564
Bid0.3982 x 200
Ask0.5744 x 200
Day's range0.5506 - 0.5800
52-week range0.4900 - 2.1300
Volume5,154,147
Avg. volume10,260,429
Market cap242.974M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Agenus Reports Fourth Quarter and Full Year 2023 Results

    LEXINGTON, Mass., March 14, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

  • Business Wire

    Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

    LEXINGTON, Mass., March 06, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.

  • Business Wire

    Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass., March 05, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.